Denmark· DK-28105484214
Abasaglar KwikPen
A insulin glargine product containing insulin glargin, registered in Denmark by Eli Lilly Nederland B.V.. The same ATC class is registered in 13 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Insulin glargine is registered in 13 of 19 countries.
Countries holding a registration under ATC A10AE04 (insulin glargine), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Insulin glargine · ATC A10AE04
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Insulin glargin
- Manufacturer
- Eli Lilly Nederland B.V.
- Country
- Denmark (DK)
- ATC code
- A10AE04
- ATC class
- Insulin glargine
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28105484214
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
433 interactions on record for insulin glargine.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Insulin glargine · interactions on record
433 records
- 15 severe
- 367 moderate
- 50 minor
Most severe, free to view
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- PrednisoloneA07EA01moderate
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A10AE04
Insulin glargine, as other registers publish it.
- DenmarkAbasaglarEli Lilly Nederland B.V.
- PolandAbasaglarEli Lilly Nederland B.V.
- IcelandAbasaglarEli Lilly Nederland B.V.*
- IcelandAbasaglarEli Lilly Nederland B.V.*
- SwitzerlandAbasaglar
- FinlandABASAGLAREli Lilly Nederland B.V.
- CzechiaABASAGLAREli Lilly Nederland B.V., Utrecht
- CzechiaABASAGLAREli Lilly Nederland B.V., Utrecht
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b42080b6-65d0-4e08-a234-7024eaf9684d GET /v1/drugs/b42080b6-65d0-4e08-a234-7024eaf9684d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "injektionsvæske, opløsning i fyldt pen",
"source": "dkma",
"strength": "100 E/ml",
"auth_role": "MOD",
"dk_drugid": "28105484214",
"substance": "Insulin glargin",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "41891"
}See everything about insulin glargine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.